For adult patients with active psoriatic arthritis (PsA)

Improves physical function

Significant mean improvements in physical function from baseline1


STUDY DESIGN INTRODUCTION

ADEPT was a 24-week randomized, double-blind, placebo-controlled study in 313 adult patients with active PsA who had inadequate response to NSAIDs. Co-primary endpoints were ACR 20 response at week 12 and mean change from baseline in mTSS for HUMIRA-treated patients at week 48 vs placebo at week 24. Patients who completed the original 24-week double-blind ADEPT study (n=285) were eligible for open-label treatment through week 144.1-4

View full study design

Mean improvement in physical function from baseline was assessed using a Health Assessment Questionnaire Disability Index (HAQ-DI) score.1,5

HAQ-DI measures the patient’s ability to perform activities such as:

HAQ-DI measures the patient’s ability to dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity over the past week.

Mean improvement from baseline in HAQ-DI score (secondary endpoint)1

Week 12

47%

mean improvement from baseline in
HUMIRA-treated patients


1%

mean improvement from baseline in placebo-treated patients

P<0.001

Week 24

49%

mean improvement from baseline in
HUMIRA-treated patients


3%

mean improvement from baseline in placebo-treated patients

P<0.001

HUMIRA 40 mg EOW (n=151)

Placebo (n=162)

Improvement is measured in this trial by a mean percentage decrease from baseline of HAQ-DI scores.

The 8 category scores are averaged to obtain the HAQ-DI score, which ranges from 0 to 3, with a higher score indicating a greater extent of functional limitations.